BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26796853)

  • 21. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
    Su Y; Wang X; Li J; Xu J; Xu L
    Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
    Yan W; Xu N; Han X; Zhou XM; He B
    Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
    Wu X; Wu G; Yao X; Hou G; Jiang F
    Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
    Xu L; Lan H; Su Y; Li J; Wan J
    Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological significance and potential drug target of T-cadherin in NSCLC.
    Wang Z; Wang B; Guo H; Shi G; Hong X
    Drug Des Devel Ther; 2015; 9():207-16. PubMed ID: 25565774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
    Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
    Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients.
    Huang T; Chen X; Hong Q; Deng Z; Ma H; Xin Y; Fang Y; Ye H; Wang R; Zhang C; Ye M; Duan S
    Sci Rep; 2015 Mar; 5():8897. PubMed ID: 25754026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
    Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
    Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocarcinoma cells by blocking PI3K-Akt pathway.
    Huang Q; Liu Z; Xie F; Liu C; Shao F; Zhu CL; Hu S
    ScientificWorldJournal; 2014; 2014():179698. PubMed ID: 24757411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA methylation pattern as important epigenetic criterion in cancer.
    Ghavifekr Fakhr M; Farshdousti Hagh M; Shanehbandi D; Baradaran B
    Genet Res Int; 2013; 2013():317569. PubMed ID: 24455281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
    Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
    Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of DNA methylation as biomarkers in the clinical management of lung cancer.
    Fleischhacker M; Dietrich D; Liebenberg V; Field JK; Schmidt B
    Expert Rev Respir Med; 2013 Aug; 7(4):363-83. PubMed ID: 23964627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA methylation and cancer diagnosis.
    Delpu Y; Cordelier P; Cho WC; Torrisani J
    Int J Mol Sci; 2013 Jul; 14(7):15029-58. PubMed ID: 23873296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer.
    Al-Temaimi RA; Jacob S; Al-Ali W; Thomas DA; Al-Mulla F
    J Histochem Cytochem; 2013 Sep; 61(9):627-38. PubMed ID: 23797051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA methylation data analysis and its application to cancer research.
    Ma X; Wang YW; Zhang MQ; Gazdar AF
    Epigenomics; 2013 Jun; 5(3):301-16. PubMed ID: 23750645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood.
    Tan S; Sun C; Wei X; Li Y; Wu Y; Yan Z; Feng F; Wang J; Wu Y
    Exp Lung Res; 2013; 39(4-5):182-90. PubMed ID: 23614702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.
    Banzai C; Nishino K; Quan J; Yoshihara K; Sekine M; Yahata T; Tanaka K;
    Int J Clin Oncol; 2014 Feb; 19(1):127-32. PubMed ID: 23494221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in cancer mortality in China: an update.
    Guo P; Huang ZL; Yu P; Li K
    Ann Oncol; 2012 Oct; 23(10):2755-2762. PubMed ID: 22492700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.
    Romero I; Martinez M; Garrido C; Collado A; Algarra I; Garrido F; Garcia-Lora AM
    J Pathol; 2012 Jul; 227(3):367-79. PubMed ID: 22451343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.